Financials data is unavailable for this security.
View more
Year on year Regenxbio Inc had revenues fall -19.94% from 112.72m to 90.24m, though the company grew net income from a loss of 280.32m to a smaller loss of 263.49m.
| Gross margin | 54.36% |
|---|---|
| Net profit margin | -283.19% |
| Operating margin | -291.58% |
| Return on assets | -41.43% |
|---|---|
| Return on equity | -71.87% |
| Return on investment | -51.75% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Regenxbio Inc fell by 62.43m. However, Cash Flow from Investing totalled 190.94m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 218.41m for operations while cash used for financing totalled 34.97m.
| Cash flow per share | -4.65 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 6.09 |
|---|---|
| Tangible book value per share | 6.09 |
More ▼
Balance sheet in USDView more
| Current ratio | 3.05 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | 0.00 |
|---|---|
| Total debt/total capital | 0.00 |
More ▼
